

vol. n.
62/1

Cited in Index Medicus / Medline
NLM ID 921440 (Pub-Med)

March
2021

Supplemento 2

Atti

2° edizione

Giornate della ricerca scientifica
e delle esperienze professionali dei giovani

Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SIItI)

17-18 dicembre 2020

JOURNAL OF PREVENTIVE MEDICINE AND HYGIENE



The Journal has been accredited,
on occasion of the 17th December
2004 Meeting of the Executive
and Scientific SIItI Councils, by the
Italian Society of Hygiene, Preventive
Medicine and Public Health

PACINI
EDITORE
MEDICINA

JOURNAL OF PREVENTIVE MEDICINE AND HYGIENE

<http://www.jpmmh.org>

Editor

Pietro Crovari, *Department of Health Sciences, University of Genoa, Italy*

Co-Editors

Roberto Gasparini, *Department of Health Sciences and Interuniversity Research Centre on Influenza and other infections, University of Genoa, Italy*

Giancarlo Icardi, *Department of Health Sciences and Interuniversity Research Centre on Influenza and other infections, University of Genoa, Italy*

International Editorial Board

Gabriella Agazzotti, *Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy*

Daniela Amicizia, *Department of Health Sciences, University of Genoa, Italy*

Roy Anderson, *FRS FMedSci, London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health Faculty of Medicine, United Kingdom*

Italo Francesco Angelillo, *Department of Experimental Medicine, Second University of Naples, Italy*

Filippo Ansaldi, *Department of Health Sciences, University of Genoa, Italy*

Paolo Bonanni, *Department of Health Sciences, University of Florence, Italy*

Rosa Cristina Coppola, *Department of Public Health, University of Cagliari, Italy*

Maria Luisa Cristina, *Department of Health Sciences, University of Genoa, Italy*

Francesco D'Agostini, *Department of Health Sciences, University of Genoa, Italy*

Silvio De Flora, *Department of Health Sciences, University of Genoa, Italy*

Àngela Dominguez, *Department de Salut Pública Facultat de Medicina, University of Barcelona, Spain*

Paolo Durando, *Department of Health Sciences, Postgraduate School in Occupational Medicine, University of Genoa and Occupational Medicine Unit, IRCCS AOU San Martino IST, Genoa, Italy*

Giovanni Gabutti, *Department of Medical Sciences, University of Ferrara, Italy*

Alberto Izzotti, *Department of Health Sciences, University of Genoa, Italy*

Silvia Majori, *Dep. Diagnostics and Public Health, University of Verona. Section of Hygiene and Preventive, Environmental and Occupational Medicine*

Nicola Nante, *Department of Molecular and Developmental Medicine, University of Siena, Italy*

Paolo Orlando, *Department of Health Sciences, University of Genoa, Italy*

Donatella Panatto, *Department of Health Sciences and Interuniversity Research Centre on Influenza and Other Infections, University of Genoa, Italy*

Vana Papaevangelou, *Pediatric Infectious Diseases Third Department of Pediatrics General University Hospital Attikon, Athens, Greece*

Gabriele Pelissero, *Department of Preventive, Occupational and Community Medicine, University of Pavia, Italy*

Mario Ramirez, *Instituto de Microbiologia Faculdade de Medicina, University of Lisboa, Portugal*

Rino Rappuoli, *GlaxoSmithKline, Siena Italy*

Laura Sticchi, *Department of Health Sciences, University of Genoa, Italy*

Fiona Timmins, *School of Nursing and Midwifery, Trinity College, Dublin, Ireland*

Pierre Van Damme, *Faculty of Medicine and Health Sciences Centre for the Evaluation of Vaccination Vaccine & Infectious Disease Institute, University of Antwerp, Belgium*

Alessandro Remo Zanetti, *Department of Biomedical Sciences for Health, University of Milan, Italy*

Editorial Staff

Daniela Amicizia, *Department of Health Sciences and Interuniversity Research Centre on Influenza and Other Infections, University of Genoa, Italy*

Piero Luigi Lai, *Department of Health Sciences and Interuniversity Research Centre on Influenza and Other Infections, University of Genoa, Italy*

Donatella Panatto, *Department of Health Sciences and Interuniversity Research Centre on Influenza and Other Infections, University of Genoa, Italy*

Section Editors

e-Health: Alexander Domnich

Environmental Hygiene: Maria Luisa Cristina

Health Care Management: Giancarlo Icardi

Health Promotion: Donatella Panatto, Giacomo Lazzeri

Health Technology Assessment: Roberto Gasparini

History of Medicine and Ethics: Mariano Martini

Hospital Hygiene: Maria Luisa Cristina

Infectious Diseases: Daniela Amicizia, Cecilia Trucchi

Molecular Epidemiology: Sebastiano La Maestra

Non Communicable Diseases: Alberto Izzotti

Nosocomial Infections: Filippo Ansaldi

Nursing: Loredana Sasso, Annamaria Bagnasco

Occupational Medicine and Hygiene: Paolo Durando, Guglielmo Dini

Pharmacoeconomics: Donatella Panatto

Prevention by Antivirals and Antibiotics: Claudio Viscoli

Public Health Laboratory Methods: Laura Sticchi

The International Board is under revision.

© Copyright by Pacini Editore Srl, Pisa, Italy

Managing Editor: Patrizia Alma Pacini

Publisher: Pacini Editore Srl, Via Gherardesca 1, 56121 Pisa, Italy

Published online March 2021

Authorization Tribunal of Genoa, Italy n. 507 - 10/6/1960

Journal registered at "Registro pubblico degli Operatori della Comunicazione" (Pacini Editore srl registration n. 6269 - 29/8/2001).



Società Italiana di Igiene,
Medicina Preventiva e Sanità Pubblica

2° EDIZIONE “GIORNATE DELLA RICERCA SCIENTIFICA E DELLE ESPERIENZE PROFESSIONALI DEI GIOVANI”

17-18 Dicembre 2020

<https://fadsiti.it/giornatedellaricercascientifica>

soggetti sani o malati di tutte le età. Sono stati esclusi articoli che hanno utilizzato tecniche in vitro, che hanno esplorato la relazione tra lattoferrina e batteri, funghi o parassiti. Per ogni studio considerato eleggibile, due revisori hanno estratto in modo indipendente le seguenti informazioni: primo autore, anno di pubblicazione, paese, famiglia di virus, scopo dello studio, caratteristiche della popolazione target, disegno dello studio, tipo e durata dell'intervento, risultati principali.

RISULTATI

Dopo la rimozione dei duplicati, 1.130 records sono stati screenati per titolo e abstract. Di questi, 166 full text sono stati valutati e 14 articoli (12 trial clinici e 2 studi di coorte) sono stati infine inclusi nella revisione sistematica. Le evidenze disponibili sono state raggruppate sulla base della famiglia virale in *Flaviviridae*, *Retroviridae*, *Reoviridae*, *Caliciviridae*, *Coronaviridae*. Si è evidenziata una considerevole eterogeneità nei metodi di reclutamento dei partecipanti e di conduzione degli studi; per quanto riguarda i *Flavivirus*, si trattava sempre di pazienti adulti con infezione da HCV nei quali la carica virale è significativamente diminuita dopo la somministrazione di lattoferrina. Due studi sui retrovirus riguardavano la popolazione pediatrica, rivelando rispettivamente una diminuzione della carica virale, un aumento dei CD4, un incremento di linfociti T e della interluchina 12. Lo studio sulla popolazione adulta con infezione da HIV ha valutato la risposta immunologica, ma senza dare risultati significativi. Dei due studi condotti sui *Reovirus*, entrambi considerando bambini sani, solo uno ha evidenziato l'influenza positiva della lattoferrina sulla severità della sintomatologia clinica, senza tuttavia migliorare significativamente l'incidenza di queste infezioni virali, così come hanno riportato nello studio condotto sui *Calicivirus*. Infine, lo studio sui *Coronavirus* ha riportato esiti positivi per quanto riguarda il miglioramento della sintomatologia clinica in seguito a somministrazione di lattoferrina.

CONCLUSIONI

I risultati preliminari di questa revisione sistematica hanno evidenziato la necessità di approfondire il ruolo della lattoferrina sulle infezioni sostenute da virus, sia sotto l'aspetto preventivo che nelle infezioni in fase attiva. In particolare, ci sono prove convincenti sulla diminuzione della carica virale nei pazienti con infezione da HCV e HIV, ma bisogna indagare meglio l'efficacia preventiva della lattoferrina sia sui bambini che sugli adulti.

BIBLIOGRAFIA

- [1] Morse JS, Lalonde T, Xu S, Liu WR. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. *Chembiochem* 2020;21:730-8.
- [2] Dong L, Shasha H, Jianjun G. Discovering drugs to treat coronavirus disease 2019 (COVID-19). *Drug Discov Ther* 2020;14:58-60.
- [3] Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. *Nutrients* 2020;12:988.
- [4] Chang R, Ng TB, Sun Z-W. Lactoferrin as potential preventative and treatment for COVID-19. *Int J Antimicrob Agents* 2020;56:106118.
- [5] Serrano G, Kochergina I, Albors A, Diaz E, Oroval M, Hueso G, Serrano JM. Liposomal lactoferrin as potential preventative and cure for COVID-19. *Int J Res Health Sci* 2020;8:8-15.
- [6] Telang S. Lactoferrin: a critical player in neonatal host defense. *Nutrients* 2018;10:1228.

- [7] Bezault J, Bhimani R, Wiprovnick J, Furmanski P. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. *Cancer Res* 1994;54:2310-2.
- [8] Hasegawa K, Motosuchi W, Tanaka S, Dosako S. Inhibition with lactoferrin of in vitro infection with human herpes virus. *Jpn J Med Sci Biol* 1994;47:73-85.

Seroprevalence of anti-SARS-CoV-2 antibodies after the first COVID-19 wave: a cross-sectional study in the province of Modena, city of a Northern Italy region

NAUSICAA BERSELLI¹, TOMMASO FILIPPINI¹,
STEFANIA PADUANO¹, MARCELLA MALAVOLTI¹,
ALBERTO MODENESE¹, FABRIZIOMARIA GOBBA¹,
PAOLA BORELLA¹, ISABELLA MARCHESI¹,
ROBERTO VIVOLI², PAOLA PERLINI², ROSSANA BELLUCCI²,
ANNALISA BARGELLINI¹, MARCO VINCETI¹

¹ Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Università di Modena e Reggio Emilia; ² Laboratorio Test di Modena

INTRODUCTION

The spread of the COVID-19 outbreak, due to infection with the coronavirus SARS-CoV-2, occurred all around the world in the spring of 2020, with extremely severe consequences in terms of hospitalizations and deaths [1]. In Italy the epidemic was first recognized on 21 February 2020 [2]. There was a first wave that mainly affected Northern Italy [3], with a rapid rise in the number of cases and a peak on 21 March, followed by a decline and stabilization of cases in June and July. Italy is currently witnessing a second wave of the outbreak throughout its entire territory [4]. In the present study, we investigated serum anti-SARS-CoV-2 antibody prevalence between 1 June and 25 September 2020 in 7,561 subjects in Modena, Northern Italy.

MATERIALS AND METHODS

We investigated 5,454 workers, who participated to testing campaign offered by their companies, and 2,107 residents who independently decided to undergo the examination at the Test Laboratory in Modena. Upon approval by the local Ethics Committee, we analyzed the results of this analytical campaign, and specifically of serological tests to detect serum anti-SARS-CoV-2 antibody in the subjects tested from 1 June to 25 September 2020. We considered both quantitative and qualitative tests carried out on these samples. We computed absolute and relative prevalence of serum antibodies against SARS-CoV-2 in the whole study population and in selected subgroups. To consider the subjects based on the professional activity to which they belong, we used the categories in the 2007 ATECO classification of economic activity [5].

RESULTS

The overall seroprevalence was 4.7%, higher in females (5.4%) than in males (4.3%), and in the oldest age groups (7.3% between 60 and 69 years, and 11.8% ≥ 70 years). Furthermore, seroprevalence proved higher in subjects tested with the quantitative test (5.8%) compared to the rapid qualitative one (2%). Among the occupational categories, we found the highest seroprevalence in healthcare workers (8.8%), dealers and vehicle repairers (5.2%) and workers in the sports sector (4.0%). Seroprevalence was lower for office workers (3.3%), people working in water supply and waste management sector (2.4%) and manufacturers (2.0%),

and even lower or null for those employed in sectors such as transport and storage, accommodation and restaurant services, and the school system.

CONCLUSIONS

The higher seroprevalence in females may indicate a greater susceptibility to infection, a lower COVID-19 lethality compared to males, or an effect of the familial, social and occupational roles of women, leading to an increased risk of contracting the virus. The steep increase in seroprevalence in the older age groups, together with the higher mortality affecting them, is of paramount relevance for the evaluation of specific protection policies for these subjects at high risk. Considering occupational risk factors, and not unexpectedly, seroprevalence was higher in healthcare workers, most exposed to SARS-CoV-2 infection, followed by dealers, vehicle repairers and sportsmen. The results in healthcare operators are in agreement with data previously observed in other studies [8-10] and may underline the high risk of infection experienced by this crucial sector and the need to increase their protective measures for these workers. We found that workers heavily involved in routine contacts with different people (clients, patients, sports opponents) had a higher seroprevalence of anti-SARS-CoV-2 antibodies. On the other hand, no excess seropositivity emerged for office workers having no contact with the public as expected, for manufacturing and construction workers, and for employees in transportation and storage. This indicates that, so far, these sectors have enforced adequate physical distancing and use of personal protective equipment to mitigate the risk of SARS-CoV-2 infection. The absence of increased risk for workers in the education sector was probably strongly favored by the limited mobility and smart working of employees during the national lockdown [11]. Interestingly, the subgroup "production of meat products" did not show any positivity to the serological test, contrary to what expected given the occurrence of small outbreaks in slaughterhouses in other regions [12,13]. In conclusion, we have assessed in detail the seroprevalence of anti-SARS-CoV-2 antibodies in an Italian area severely hit by the first wave of Covid-19, the Emilia-Romagna region. This will also allow to estimate Covid-19 infection fatality ratio, since so far the only estimate available in this area has been case-fatality ratio [14].

REFERENCES

- [1] WHO. WHO Director-General's opening remarks at the media briefing on COVID-19. 11 March 2020.
- [2] Vinceti M, Filippini T, Rothman KJ, Ferrari F, Goffi A, Maffei G, Orsini N. Lockdown timing and efficacy in controlling COVID-19 using mobile phone tracking. *EClinicalMedicine* 2020;25:100457.
- [3] Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *JAMA* 2020;323:1775-6.
- [4] Task force COVID-19 del Dipartimento Malattie Infettive e Servizio di Informatica ISdS, Epidemia COVID-19, Aggiornamento nazionale 6 ottobre 2020 - ore 11:00.
- [5] ISTAT. Classificazione delle attività economiche Ateco 2007 derivata dalla Nace Rev. 2. 2009.
- [6] Fiore JR, Centra M, De Carlo A, Granato T, Rosa A, Sarno M, De Feo L, Di Stefano M, Errico M, Caputo SL, De Nittis R, Arena F, Corso G, Margaglione M, Santantonio TA. Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2. *J Med Virol* 2021;93:1739-42.
- [7] Perez-Lopez FR, Tajada M, Saviron-Cornudella R, Sánchez-Prieto M, Chedraui P, Terán E. Coronavirus disease 2019 and gender-related mortality in European countries: a meta-analysis. *Maturitas* 2020;141:59-62.
- [8] Sotgiu G, Barassi A, Miozzo M, Saderi L, Piana A, Orfeo N, Colosio C, Felisati G, Davì M, Gerli AG, Centanni S. SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital. *BMC Pulm Med* 2020;20:203.
- [9] Modenese A, Gobba F. Increased risk of COVID-19-related deaths among general practitioners in Italy. *Healthcare (Basel)* 2020;8:155.
- [10] Consonni D, Bordini L, Nava C, Todaro A, Lunghi G, Lombardi A, Magioni D, De Palo F, Guerrieri L, Gatti M, Serra D, Polonioli M, Pratò S, Muscatello A, Bandera A, Auxilia F, Castaldi S. COVID-19: what happened to the healthcare workers of a research and teaching hospital in Milan, Italy? *Acta Biomed* 2020;91:e2020016.
- [11] Presidente del Consiglio dei Ministri, DPCM 22 marzo 2020.
- [12] Dyal JW, Grant MP, Broadwater K, Bjork A, Waltenburg MA, Gibbins JD, Hale C, Silver M, Fischer M, Steinberg J, Basler CA, Jacobs JR, Kennedy ED, Tomasi S, Trout D, Hornsby-Myers J, Oussayef NL, Delaney LJ, Patel K, Shetty V, Kline KE, Schroeder B, Herlihy RK, House J, Jervis R, Clayton JL, Ortbahn D, Austin C, Berl E, Moore Z, Buss BF, Stover D, Westergaard R, Pray I, DeBolt M, Person A, Gabel J, Kittle TS, Hendren P, Rhea C, Holsinger C, Dunn J, Turabelidze G, Ahmed FS, deFijter S, Pedati CS, Rattay K, Smith EE, Luna-Pinto C, Cooley LA, Saydah S, Precely ND, Maddox RA, Lundeen E, Goodwin B, Karpathy SE, Griffing S, Jenkins MM, Lowry G, Schwarz RD, Yoder J, Peacock G, Walke HT, Rose DA, Honein MA. COVID-19 among workers in meat and poultry processing facilities - 19 States, April 2020. *MMWR Morb Mortal Wkly Rep* 2020;69(18).
- [13] Middleton J, Reintjes R, Lopes H. Meat plants-a new front line in the covid-19 pandemic. *BMJ* 2020;370:m2716.
- [14] Fonzo M, Bertoncetto C, Baldo V. Mortality from COVID-19: are we getting closer to the true value? *Pathog Glob Health* 2020;114:347-8.

Infezione da HIV e prevenzione secondaria: risultati preliminari di un'indagine condotta negli studenti universitari

ANTONELLA OLIVERIO¹, FRANCESCA LICATA¹,
CARMELLO GA NOBILE², AIDA BIANCO¹

¹ Dipartimento di Scienze della Salute, Università "Magna Graecia" di Catanzaro; ² Dipartimento di Farmacia e Scienze della Salute e della Nutrizione, Università della Calabria

INTRODUZIONE

In Europa e nel mondo, sono stati messi a punto programmi per aumentare l'adesione ai test di diagnosi precoce dell'infezione sostenuta dal virus dell'immunodeficienza umana (HIV), così da ridurre il numero di infezioni non diagnosticate o diagnosticate tardivamente [1]. La diagnosi precoce dell'infezione da HIV porterebbe, infatti, a sostanziali benefici individuali e di sanità pubblica [2,3], rendendo più efficace la terapia antiretrovirale e offrendo un'aspettativa di vita paragonabile a quella della popolazione generale. L'incidenza più alta di nuove diagnosi di HIV in Italia si riscontra nella fascia di età 25-29 anni (10,4/100.000) [4]. Obiettivo primario del presente studio è stato, pertanto, valutare le conoscenze degli studenti universitari.